This site is intended for healthcare professionals

Heart Failure: News

 
 

  • Study Identifies CV Comorbidities Linked to Dermatomyositis The results "represent potential areas for preventative intervention," the researchers wrote.
  • Medicare Bundled Payment Model Fails to Boost HF Outcomes Medicare's bundled payment model was not associated with changes in process-of-care measures or early outcomes after hospitalization for heart failure, a new study reported.
  • Hospital Adverse Events Rise Post Private Equity Acquisition However, in-hospital mortality rates were not significantly different at private equity hospitals compared with control hospitals.
    4
  • How Accurately Can ChatGPT Answer Cardiac Arrest Queries? ChatGPT's ability to respond to cardiac arrest inquiries by survivors, their relatives, and lay rescuers was investigated, revealing its accuracy and limitations.
  • Alert Positive Topline Results for SEQUOIA-HCM Trial in OHCM Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
    1
  • AHA Names Top CVD Advances for 2023 Advances in stroke, a novel antihypertensive, and new evidence that diabetes drugs may offer CVD benefits for those without diabetes are among the top developments in 2023, on the AHA's annual list.
  • Alert FDA Expands Label for CVRx Barostim System in HF The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.
  • Noninvasive Ultrasound Benefits Calcified Aortic Valves A recently developed technique reduces calcification by as much as 20% and could provide an alternative to valve replacement for some patients.
    4
  • Device-Detected Atrial High-Rate Episodes Tied to Mortality Atrial high-rate episodes are associated with more than twice the risk for mortality in patients with an implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator.
  • Study to Examine Routine ICD Implantation Post Heart Attack The emergence of new medicinal treatments may have changed the risk-benefit ratio of routine ICD implantation in patients with a severely abnormal LVEF after a heart attack.
    2
  • Systemic Bias in AI Models May Undermine Diagnostic Accuracy However, standard AI model predictions enhanced diagnostic accuracy by 4.4%.
  • Patients Facing Death Are Choosing a Lifesaving Heart Device The HeartMate 3 is considered the safest mechanical heart pump of its kind, but a federal database has more than 4500 reports in which the medical device may have caused a patient's death.
    10
  • GLP-1 RAs for CVD: Are Cardiologists Ready? The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
    2
  • Tafamidis May Help Protect Cardiac Function in ATTR-CM Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.
  • Transcatheter Tricuspid Repair Improved Quality of Life Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.
  • ADA Issues New Screening, Obesity Management Recommendations Updates to the American Diabetes Association's Standards of Care for 2024 include multiple new screening recommendations, as well as new obesity management guidance and other revisions.
    3
  • Antihypertensives Show Similar Long-Term Mortality Rates Long-term data showed negligible differences in mortality among hypertensive adults treated with thiazide-type diuretics, calcium channel blockers, or angiotensin-converting enzyme inhibitors.
    11
  • New Cardiology Certification Board: What's the Plan? The proposal by the major cardiovascular societies to form a new certification board represents a revolution in the field of CME and assessment of competency. What is known so far?
    3
  • Sotatercept Endorsed for PAH by ICER Drug's novel mechanism of action raises hopes of disease-modifying activity, but long-term cost-effectiveness rests on improvement in functional status.
  • Next Up for PCPs: Managing CKM An AHA presidential advisory introduced the concept of cardiovascular-kidney-metabolic health, with PCPs as key providers.
    7
  • Analysis Supports Link Between Psoriasis and OSA Several hypotheses may explain the connection, such as the presence of inflammatory mediators and nocturnal cytokine secretion, according to the authors.
  • No Benefit of Levothyroxine in Heart Donors New data challenge the common practice of levothyroxine administration in potential heart donors after brain death to preserve heart function and make more hearts available for transplantation.
    1
  • ACC/AHA Issue Updated Atrial Fibrillation Guideline The new guideline proposes a new way to classify AF, emphasizes the importance of early rhythm control and lifestyle modification, and gives catheter ablation a Class 1 indication.
    7
  • Ohio Group Scores Record Hypertension Control Rates Artificial intelligence is vastly improving blood pressure control at one Midwestern primary care practice. Could your group do the same?
    11
  • Late-Life Increases in Pulmonary Pressure, Hypertension Age-related increases in pulmonary artery systolic pressure occur in concert with worsening left ventricular diastolic dysfunction and contribute to late-life dyspnea, new data show.
  • TCT 2023 Transapical Valve Replacement Relieves Mitral Regurgitation Transapical mitral valve replacement by catheter eliminated mitral regurgitation and improved hemodynamics in a frail high-risk population, results of the SUMMIT trial show.
  • ACR 2023 Conditional Recommendations Rule in New SARD ILD Guidelines In spring 2024, the ACR is expected to release guidelines to help inform the screening, monitoring, and treatment of interstitial lung disease (ILD) in people with SARDs.
  • AHA 2023 Cardiologists, Patients Can Talk Drug Costs A carefully tailored program in which physicians talked with heart failure (HF) patients about the cost of their medications improved medication adherence.
  • Long-Term Use of ADHD Meds and CVD Risk: New Data Despite previous mixed findings, results of a large Swedish study show an increased risk for CVD with long-term use of medications, especially stimulants, to treat attention-deficit/hyperactivity disorder.
    17
  • AHA 2023 AI Voice Analysis App May Detect Worsening HF Early Voice analysis with an app that uses artificial intelligence may provide early warning of acute decompensated heart failure, researchers suggest. But these are early days, a cardiologist cautions.
  • AHA 2023 'Smart' Stethoscope Spots Peripartum Cardiomyopathy Screening with an AI-enhanced digital stethoscope doubled the diagnoses of life-threatening peripartum cardiomyopathy in Nigeria, where the incidence is the highest in the world.
  • AHA 2023 Alternative Antirejection Regimen in Pediatric Heart Transplant Results of the head-to-head TEAMMATE trial show the combination of everolimus and low-dose tacrolimus can be considered an alternative to MMF plus tacrolimus in pediatric heart transplant.
  • PREVENT: AHA's New Risk Calculator Incorporates CKM Health The new cardiovascular disease risk equations start at age 30, include measures of kidney and metabolic health, add heart failure, and remove race from the equations.
    11
  • AHA 2023 Single Injection Reduces Blood Pressure for 6 Months The RNA interference therapeutic targeting synthesis of angiotensinogen lowered BP in adults with mild to moderate hypertension for up to 6 months after one dose in the phase 2 KARDIA-1 study.
    26
  • Kidney Week 2023 Albuminuria Reduction Fuels Finerenone's Kidney Benefits The findings of the mediation analyses underscore the important role that albuminuria plays in the nephropathy and related comorbidities associated with type 2 diabetes and CKD.
  • ACR 2023 Study Takes Fine-Grained Look at MACE Risk With GCs in RA 'Up to half of RA patients in the United States use long-term glucocorticoids despite previous work suggesting they increase MACE in a dose-dependent way.'
    1
  • AHA 2023 More Evidence of Better Outcomes With 120 mm Hg BP Target Intensive lowering of blood pressure to a systolic target < 120 mm Hg reduced cardiovascular events among high-risk individuals by 12% vs a target < 140 mm Hg in the ESPRIT trial.
    10
  • T2D: Real Benefits of New Oral Antidiabetic Drugs Could combining SGLT2 inhibitors with GLP-1R agonists have a cardioprotective and nephroprotective effect for patients with type 2 diabetes?
  • ACR 2023 Pregnancy in Rheumatic Disease Quadruples CVE Risk Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than did pregnant individuals without these conditions.
  • AHA 2023 Dropping Aspirin Cuts Bleeding in LVAD Patients A randomized trial evaluating vitamin K therapy with aspirin or placebo with a left ventricular assist device shows avoiding aspirin reduced bleeding without increasing thrombotic risk.